Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Liver expression data from 31 mouse strains treated with vehicle or isoniazid for 3 days

ABSTRACT: Isoniazid induced varying degrees of hepatic steatosis in an inbred strain Mouse Diversity Panel (MDP) study. RNA was isolated from all animals for analysis of gene expression changes in the liver. The objective of this study was to identify gene expression changes that drive isoniazid-induced steatosis.

ORGANISM(S): Mus musculus

PROVIDER: GSE55489 | GEO | 2014/06/03

SECONDARY ACCESSION(S): PRJNA239764

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Liver expression data from 31 mouse strains treated with vehicle or isoniazid for 3 days

Project description:Isoniazid induced varying degrees of hepatic steatosis in an inbred strain Mouse Diversity Panel (MDP) study. RNA was isolated from all animals for analysis of gene expression changes in the liver. The objective of this study was to identify gene expression changes that drive isoniazid-induced steatosis. 235 total samples from 31 strains were analyzed: N=4 per treatment and strain, except isoniazid-treated LP/J (N=3), PL/J (N=3), SM/J (N=2), NON/LtJ (N=3), LG/J (N=3), MA/MyJ (N=2), RIIIS/J (N=3), SEA/GnJ (N=2), and A/J (N=2) animals where animals that died before the completion of the study were excluded from data analysis; 13 of 31 strains exhibited findings of isoniazid-induced steatosis and were coded as responders.

2014-06-03 | E-GEOD-55489 | biostudies-arrayexpress

Liver expression data from four mouse strains treated with vehicle or PF-04287881 for seven days

2016-10-21 | GSE52620 | GEO

Liver expression data from four mouse strains treated with vehicle or PF-04287881 for seven days

Project description:PF-04287881 induced varying degrees of liver necrosis and phospholipidosis in a 34-inbred strain Mouse Diversity Panel (MDP) study. Four strains with differing susceptibilities to these phenotypes (MA/MyJ, NZW/LacJ, SM/J, WSB/EiJ) were selected for analysis of gene expression changes in the liver. The objective of this study was to identify gene expression changes that drive PF-04287881-induced liver injury. Thirty-one total samples were analyzed: N=4 per treatment and strain, except PF-04287881-treated WSB/EiJ (N=3) where one animal died before the completion of the study due to gavage error. Two strains exhibited findings of PF-04287881-induced Kupffer cell vacuolation and were coded as phospholipidosis responders (MA/MyJ and NZW/LacJ). One strain exhibited findings of single cell necrosis and was coded as a necrosis responder (NZW/LacJ).

2016-10-21 | E-GEOD-52620 | biostudies-arrayexpress

Effect of addition of cysteine to isoniazid treatment of Mycobacterium tuberculosis

Project description:Transcriptional profiling of Mycobacterium tuberculosis H37Rv after 4 hours of combination isoniazid and cysteine treatment relative to treatment with isoniazid alone.

2017-03-27 | GSE86184 | GEO

Mycobacterium tuberculosis transcriptional response to Isoniazid

Project description:Mycobacterium tuberculosis transcriptional response to Isoniazid

| PRJNA694989 | ENA

Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid

Project description:Tuberculosis is a global health threat that affects millions of people every year, and treatment-limiting toxicity remains a considerable source of treatment failure. Recent reports have characterized the nature of hPXR-mediated hepatotoxicity and systemic toxicity of antitubercular drugs. The antitubercular drug isoniazid plays a role in such pathologic states as acute intermittent porphyria, anemia, hepatotoxicity, hypercoagulable states (deep vein thrombosis, pulmonary embolism, or ischemic stroke), pellagra (vitamin B3 deficiency), peripheral neuropathy, and vitamin B6 deficiency. However, the mechanisms by which isoniazid administration leads to these states are unclear. To elucidate the mechanism of rifampicin- and isoniazid-induced liver and systemic injury, we performed tandem mass tag mass spectrometry-based proteomic screening of mPxr–/– and hPXR mice treated with combinations of rifampicin and isoniazid. Proteomic profiling analysis suggested that the hPXR liver proteome is affected by antitubercular therapy to disrupt [Fe–S] cluster assembly machinery, [2Fe–2S] cluster-containing proteins, CYP450 enzymes, heme biosynthesis, homocysteine catabolism, oxidative stress responses, vitamin B3 metabolism, and vitamin B6 metabolism. These findings provide insight into the etiology of some of these processes and potential targets for subsequent investigations.

2020-07-19 | PXD019505 | Pride

Mycobacterium tuberculosis transcriptional response to Isoniazid

Project description:The ability of Mycobacterium tuberculosis (Mtb) to adopt heterogeneous physiological states, underlies it’s success in evading the immune system and tolerating antibiotic killing. Drug tolerant phenotypes are a major reason why the tuberculosis (TB) mortality rate is so high, with over 1.8 million deaths annually. To develop new TB therapeutics that better treat the infection (faster and more completely), a systems-level approach is needed to reveal the complexity of network-based adaptations of Mtb. Here, we report the transcriptional response of Mtb to the drug isoniazid. We performed transcriptomic sequencing (RNA-seq) on Mtb bacilli at 4, 24, 72 h following exposure to the drug.

2021-12-15 | GSE165581 | GEO

Identification And Characterization Of Histone Mark Isonicotinylation That Is Induced By Anti-tuberculosis First-line Drug Isoniazid

Project description:We identified and characterized a previously undescribed histone mark, lysine isonicotinylation. This histone mark could be modulated by isoniazid (INH), aa preferred and widely used drug for the treatment of latent tuberculosis (TB), via generation of isonicotyl CoA. By RNA-seq analysis, we demonstrate that histone lysine isonicotinylation marks are involved in regulation of gene expression and associated with diverse biological processes. Thereby,enhanced isonicotinylation may represent a mechanism underlying side effects in patients who taking long-term isoniazid and may also increase risk for cancers.

2021-08-11 | GSE168473 | GEO

Effects of manganese and its concomitant administration with isoniazid on macrophages infected with Mycobacterium tuberculosis

Project description:In order to study the effect of manganese on the immunity of macrophages, we established a model of infection with Mycobacterium tuberculosis and treated it with manganese and isoniazid for 12 hours

2022-08-26 | GSE211666 | GEO

Chemical disarming of isoniazid resistance in Mycobacterium tuberculosis

Project description:Chemical disarming of isoniazid resistance in Mycobacterium tuberculosis

| PRJNA532912 | ENA